致编辑的信。 - Suppr

Letter to the editor.

作者信息

Goldberg Yigal Paul, Cohen Charles J, Namdari Rostam, Price Nicola, Cadieux Jay A, Young Clint, Sherrington Robin, Pimstone Simon Neil

机构信息

Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada.

出版信息

Pain. 2014 Apr;155(4):837-838. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13.

DOI:10.1016/j.pain.2014.01.003

PMID:24434731

Abstract

摘要

相似文献

Letter to the editor.

Pain. 2014 Apr;155(4):837-838. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13.

A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity.

J Physiol. 2007 Jun 15;581(Pt 3):1019-31. doi: 10.1113/jphysiol.2006.127027. Epub 2007 Apr 12.

Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker.

Pain. 2012 Jan;153(1):80-85. doi: 10.1016/j.pain.2011.09.008. Epub 2011 Oct 28.

Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.

Klin Padiatr. 2012 Sep;224(5):309-12. doi: 10.1055/s-0031-1287823. Epub 2011 Dec 14.

Letter to the editor on NaV1.8.

Circ Res. 2012 Sep 28;111(8):e230; author reply e231. doi: 10.1161/CIRCRESAHA.112.278358.

Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.

Clin Exp Dermatol. 2009 Dec;34(8):e640-2. doi: 10.1111/j.1365-2230.2009.03355.x. Epub 2009 Jun 22.

A case of primary erythermalgia with encephalopathy.

J Neurol. 2009 Oct;256(10):1767-8. doi: 10.1007/s00415-009-5188-1. Epub 2009 Jun 17.

[How close are we from achieving the goal of eliminating pain--a channelopathy revealed the origin of pain].

Sheng Li Ke Xue Jin Zhan. 2007 Jul;38(3):199-201.

[Erythromelalgia: Diagnosis and therapeutic approach].

Rev Med Interne. 2017 Mar;38(3):176-180. doi: 10.1016/j.revmed.2016.08.012. Epub 2016 Sep 14.

[Myotonic disorder and channelopathy].

Nihon Naika Gakkai Zasshi. 2004 Mar 10;93(3):510-4. doi: 10.2169/naika.93.510.

引用本文的文献

Inhibition of Na1.7: the possibility of ideal analgesics.

RSC Med Chem. 2022 Aug 1;13(8):895-920. doi: 10.1039/d2md00081d. eCollection 2022 Aug 17.

Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na1.7.

J Med Chem. 2019 Oct 10;62(19):8695-8710. doi: 10.1021/acs.jmedchem.8b01906. Epub 2019 May 7.

Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype.

Clin J Pain. 2017 Apr;33(4):310-318. doi: 10.1097/AJP.0000000000000408.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Letter to the editor.

作者信息

Goldberg Yigal Paul, Cohen Charles J, Namdari Rostam, Price Nicola, Cadieux Jay A, Young Clint, Sherrington Robin, Pimstone Simon Neil

机构信息

Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada.

出版信息

Pain. 2014 Apr;155(4):837-838. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13.

DOI:10.1016/j.pain.2014.01.003

PMID:24434731

Abstract

摘要

相似文献

Letter to the editor.

Pain. 2014 Apr;155(4):837-838. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13.

A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity.

J Physiol. 2007 Jun 15;581(Pt 3):1019-31. doi: 10.1113/jphysiol.2006.127027. Epub 2007 Apr 12.

Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker.

Pain. 2012 Jan;153(1):80-85. doi: 10.1016/j.pain.2011.09.008. Epub 2011 Oct 28.

Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.

Klin Padiatr. 2012 Sep;224(5):309-12. doi: 10.1055/s-0031-1287823. Epub 2011 Dec 14.

Letter to the editor on NaV1.8.

Circ Res. 2012 Sep 28;111(8):e230; author reply e231. doi: 10.1161/CIRCRESAHA.112.278358.

Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.

Clin Exp Dermatol. 2009 Dec;34(8):e640-2. doi: 10.1111/j.1365-2230.2009.03355.x. Epub 2009 Jun 22.

A case of primary erythermalgia with encephalopathy.

J Neurol. 2009 Oct;256(10):1767-8. doi: 10.1007/s00415-009-5188-1. Epub 2009 Jun 17.

[How close are we from achieving the goal of eliminating pain--a channelopathy revealed the origin of pain].

Sheng Li Ke Xue Jin Zhan. 2007 Jul;38(3):199-201.

[Erythromelalgia: Diagnosis and therapeutic approach].

Rev Med Interne. 2017 Mar;38(3):176-180. doi: 10.1016/j.revmed.2016.08.012. Epub 2016 Sep 14.

[Myotonic disorder and channelopathy].

Nihon Naika Gakkai Zasshi. 2004 Mar 10;93(3):510-4. doi: 10.2169/naika.93.510.

引用本文的文献

Inhibition of Na1.7: the possibility of ideal analgesics.

RSC Med Chem. 2022 Aug 1;13(8):895-920. doi: 10.1039/d2md00081d. eCollection 2022 Aug 17.

Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na1.7.

J Med Chem. 2019 Oct 10;62(19):8695-8710. doi: 10.1021/acs.jmedchem.8b01906. Epub 2019 May 7.

Clin J Pain. 2017 Apr;33(4):310-318. doi: 10.1097/AJP.0000000000000408.

Letter to the editor.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Letter to the editor.

作者信息

机构信息

出版信息

相似文献

引用本文的文献